Skip to main content

Table 2 Clinical characteristics and cell-staining characteristics of patients whose CTCs were evaluated by ImageStreamX

From: Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer

Patient ID

Prior therapies*

PSA (ng/mL)

EpCAM + Events

CTCs (%)

Mean AR intensity#(STDev)

Median AR intensity#(Range)

AR-high CTCs (%)

Mean SI (STDev)

Median SI (Range)

12077

L, B

168.4

5

4 (80)

117262 (120651)

89033 (29879-322996)

5 (100)

0.67 (1.67)

-0.09 (-0.43-3.55)

12076

L, B, K, A

41.16

115

114 (99)

337937 (286897)

253104 (-6509-1427349)

108 (94)

-0.12 (0.85)

-0.25 (-1.79-2.31)

12079

L, B, S

32.24

104

96 (92)

25456 (36815)

11486 (1096-193627)

63 (61)

0.72 (1.06)

0.57 (-0.78-4.27)

12078

L, B, K

11.12

33

27 (82)

3202 (12736)

216 (-9849-56081)

5 (15)

0.97 (1.21)

0.95 (-0.98-2.06)

12080

L, B, D, C, A, E

554

0

NA

NA

NA

NA

NA

NA

12081

L, D, C

275.4

36

24 (67)

33078 (58419)

4115 (-12080-240098)

16 (44)

-0.05 (1.51)

-0.44 (-1.77-3.79)

12082

B, S

5.78

18

11 (61)

59487 (213913)

1437 (-6856-913784)

6 (33)

0.39 (0.94)

0.21 (-0.62-1.64)

12083

L, B, A, E

522.3

12

11 (92)

38260 (29857)

30748 (3725-92097)

9 (75)

0.3 (1.11)

-0.21 (-0.98-2.39)

12084

L

164.1

24

16 (67)

78782 (214426)

795 (-5122-800180)

8 (33)

0.6 (1.6)

0.17 (-1.02-3.63)

12081

L, D, C

382.6

15

5 (33)

-2323 (4049)

-2592 (-10466-4384)

0

NA

NA

12079

L, B, S

39.3

0

NA

NA

NA

NA

NA

NA

12086

B, L, K, D, A, E, Sa

1152

121

116 (96)

5674 (17971)

4256 (-13238-182505)

13 (11)

0.39 (0.66)

0.6 (-0.93-1.13)

12087

L, B

20.35

35

35 (100)

-11351 (21968)

-7673 (-68443-33422)

4 (11)

-0.46 (0.63)

-0.31 (-1.33-0.12)

12086

B, L, K, D, A, E, Sa

1320

11

11 (100)

115581 (88954)

102918 (46540-360131)

11 (100)

-0.36 (0.44)

-0.45 (-0.9-0.64)

12088

L, B, D

0.06

21

18 (86)

254074 (980505)

3184 (-1368-4502881)

4 (19)

-0.2 (2.65)

0.99 (-4.17-1.38)

12028-101

L, B, D, A, E

37.23

50

48 (96)

241547 (1561372)

4910 (-3059-11054469)

12 (24)

0.58 (1.51)

0.35 (-1.88-3.73)

12064-102

L, B, K, A, C

6.33

4

3 (75)

55055 (63046)

44257 (1328-130379)

2 (50)

3.74 (0.35)

3.74 (3.49-3.99)

12072-103

B, L, A, D

20.59

220

215 (98)

21851 (48606)

7965 (-45736-465037)

92 (42)

-0.1 (0.64)

-0.17 (-1.2-2.06)

12080-104

L, B, D, C, A, E

1040

3

2 (67)

81694 (72851)

108774 (-819-137127)

2 (67)

2.36 (0.43)

2.36 (2.06-2.67)

14093

Ci/Et, To, Et/Te

1.83

7

6 (86)

5566 (12133)

2578 (-8042-29243)

2 (29)

-0.12 (0.36)

-0.12 (-0.38-0.13)

12027-105

L, B, N, K, D/Da, A, E, R

489.8

40

40 (100)

7995 (31246)

3127 (-62338-124132)

5 (13)

1.32 (0.87)

1.65 (0.3-2.34)

14093

Ci/Et, To, Et/Te

1.98

23

22 (96)

500281 (2345906)

3774 (-9141-11261273)

8 (35)

-0.33 (1.54)

0.06 (-3.94-1.17)

12064-102

L, B, K, A, C

6.84

411

408 (99)

11281 (21967)

7020 (-6031-267789)

115 (28)

0.74 (0.52)

0.8 (-0.75-1.82)

12072-103

B, L, A, D

25.8

30

30 (100)

12437 (37826)

4871 (-19268-203291)

8 (27)

0.34 (0.68)

0.19 (-0.29-1.78)

12088

L, B, D

0.06

100

99 (99)

5505 (15912)

1670 (-13453-118622)

13 (13)

0.01 (0.61)

-0.17 (-0.89-1.3)

14092

L, B, K, N, A, R

498.7

13

11 (85)

51770 (97952)

689 (-60783-230484)

5 (38)

1.86 (0.82)

2.03 (0.48-2.6)

12028-101

L, B, D, A, E

46.31

29

27 (93)

23411 (69628)

4050 (-5317-359215)

7 (24)

0.92 (1.22)

0.37 (-0.62-2.85)

12076-106

L, B, K, A, D

9.33

59

59 (100)

29569 (74779)

9686 (-24144-356079)

29 (49)

1.09 (0.65)

1.05 (-0.11-3.43)

14090

L, B, N, S, A

6.81

10

8 (80)

41168 (90507)

-4692 (-83596-201844)

4 (40)

2.38 (0.52)

2.38 (1.76-3.02)

14089

L, B

5.06

11

9 (82)

192342 (687361)

-2246 (-149355-2254943)

3 (27)

2.33 (1.29)

1.71 (1.47-3.82)

14089

L, B

5.87

8

2 (25)

1953000 (5025861)

218121 (-25632-14383254)

6 (75)

1.02 (1.71)

1.53 (-2.35-2.49)

  1. Thirty-one blood draws from 20 patients were evaluated by ImageStreamX technology, of which 29 blood draws from 20 patients had CTCs identified. SI = similarity index.
  2. *Prior therapies: A = abiraterone, B = bicalutamide, C = cabazitaxel, Ci = cisplatin, D = docetaxel, Da = dasatinib, E = enzalutamide, Et = etoposide, K = ketoconazole, L = LHRH agonist, N = nilutamide, R = radium223, S = sipuleucel-T, Sa = samarium, Te = temozolemide, To = topotecan.
  3. #Negative values are due to compensation within ImageStreamX.